MedPath

Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses

Phase 2
Completed
Conditions
Actinic Keratosis
Registration Number
NCT00375739
Lead Sponsor
Peplin
Brief Summary

The purpose of this study is to determine whether topical application of PEP005 is safe for the treatment of actinic keratoses.

Detailed Description

Actinic keratoses (AK) is a common skin condition characterized by rough, scaly patches or sores on the top layer of the skin which if left untreated can progress to skin cancer. Current treatments can cause scarring and hypopigmentation, be inconvenient, or require long treatment duration. Non-invasive alternative therapy for treatment of AK lesions is thus being researched.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
200
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Safety
Secondary Outcome Measures
NameTimeMethod
Resolution of AK

Trial Locations

Locations (21)

Medical Affiliated Research Center, Inc.

🇺🇸

Huntsville, Alabama, United States

Radiant Research

🇺🇸

Greer, South Carolina, United States

Burke Pharmaceutical Research

🇺🇸

Hot Springs, Arkansas, United States

Advanced Dermatology and Cosmetic Surgery

🇺🇸

Clermont, Florida, United States

Dermatology Associates and Research

🇺🇸

Coral Gales, Florida, United States

North Florida Dermatology Associates P.A.

🇺🇸

Jacksonville, Florida, United States

Park Avenue Dermatology, PA

🇺🇸

Orange Park, Florida, United States

Dermatology Associates of Tallahassee

🇺🇸

Tallahassee, Florida, United States

Palm Beach Aesthetics

🇺🇸

West Palm Beach, Florida, United States

Medaphase, Inc

🇺🇸

Newnan, Georgia, United States

Scroll for more (11 remaining)
Medical Affiliated Research Center, Inc.
🇺🇸Huntsville, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.